Register D — Investment writeup. Pre-delivery checklist: redundancy sweep done, word justification done, guide pass done. > Date: April 26, 2026 > Source documents: 2025 DEF 14A proxy, salary.com compensation data, Form 4 insider transactions, SEC EDGAR filings (CIK: 1120914), board of directors p…
Register D — Investment writeup. Pre-delivery checklist: redundancy sweep done, word justification done, guide pass done. Date: April 26, 2026 Source documents: 2025 DEF 14A proxy, salary.com compensation data, Form 4 insider transactions, SEC EDGAR filings (CIK: 1120914), board of directors page (pdf.com/company/board-of-directors/)
| Name | Role | Shares | % Outstanding | Est. Value @ $46 | How Acquired |
|---|---|---|---|---|---|
| John K. Kibarian | CEO, Co-Founder | 2,562,474 | ~6.5% | ~$117.9M | Founder stake + minimal grants (no equity since 2003) |
| Kimon Michaels | EVP Products, Co-Founder | Not separately disclosed | Est. ~1-2% | Est. ~$20-40M | Founder stake |
| Andrzej Strojwas | CTO | 83,613 (direct, post July 2025) | <0.3% | ~$3.8M | Grants over long tenure |
| Adnan Raza | CFO | Not separately disclosed | Est. <0.5% | Est. ~$5-10M | Equity grants since 2020 |
| Insider aggregate | All insiders | ~3.7M (est.) | ~9.4% | ~$170M | Mix of founder stakes + grants |
Net insider buying vs. selling — last 12 months:
The single most important finding in this section:
John Kibarian purchased 50,000 shares at $22.11–$22.80/share on February 24–25, 2025 (total ~$1.13M investment), when the stock was near its 52-week low of $21.69 following a ~30% six-month decline. This is a clear open-market purchase with personal/trust capital. The purchase was made after the secureWISE acquisition announcement (February 19, 2025) — meaning Kibarian was buying into uncertainty, not selling into strength.
The timing and size of this purchase — $1.13M of his own money near a 52-week low immediately after announcing the company’s largest-ever acquisition — is a strong confidence signal. This is the behavior of a founder who believes the market is undervaluing the acquisition rationale and the company’s trajectory.
Kibarian’s holding (via The John Kibarian and Gloria Chen Trust): After these purchases, total holdings exceed 2.5M shares. At $46, this is ~$115-118M — his primary wealth vehicle by a wide margin.
Strojwas July 2025 transaction: An internal transaction was reported July 1, 2025. Nature (exercise/award vs. sale) not confirmed from search data; direct holdings stood at 83,613 shares post-transaction. No large sale flagged.
Raza Form 4s: Not identified as a notable seller in public searches. Granted equity grants are his primary compensation; typical vesting and sell activity expected.
10b5-1 plans: Not identified in public searches. Should be verified in SEC EDGAR Form 4 filings directly.
Assessment: Ownership quality is high. Kibarian’s wealth is overwhelmingly tied to PDFS outcomes, he has not received equity grants since 2003 (conserving for employees), and his recent open-market purchase near a 52-week low is the clearest possible skin-in-the-game signal. This is not an executive whose financial interest is primarily in cash salary or grant-driven dilution.
| Name | Holdings in PDFS | Other Notable Holdings | Where Is the Majority? |
|---|---|---|---|
| Kibarian | ~$118M (est., ~6.5%) | No material outside public company stakes identified | PDFS — overwhelmingly |
| Michaels | Est. ~$20-40M (co-founder stake) | No material outside holdings identified | PDFS |
| Strojwas | ~$3.8M (grants over 25+ years) | No other public company stakes identified | PDFS (by career if not absolute wealth) |
| Raza | Est. ~$5-10M (grants since 2020) | Prior Synaptics equity likely largely liquidated | PDFS for current incentives |
Key conclusions: - Kibarian and Michaels have the vast majority of their net worth in PDFS — this is standard founder behavior and a strong alignment signal - No identified cross-holdings in customers (Intel, TSMC, Samsung), suppliers, or competitors - No board seats or advisory roles in entities that transact with PDFS identified - No “elsewhere” stakes that would dilute their focus or create conflicts
Search scope: SEC EDGAR CIK 1120914 (proxy, 10-K related-party disclosures, Form 4 filings), public records, management backgrounds.
Findings: No related entities with overlapping management or insider control identified. Standard subsidiary structure (wholly-owned operating subsidiaries: Cimetrix, secureWISE, Exensio Analytics). No shell entities holding IP, real estate, or key assets identified.
IP licensing to insider entities: None identified. Consulting fees to insider-controlled entities: None identified. Management fees or royalties flowing to insiders: None identified. Related-party leases: None identified.
Assessment: Clean. This is a straightforward founder-led software company. No evidence of revenue circularity, asset migration, or management fee extraction patterns.
PDF Solutions, Inc. (NASDAQ: PDFS, CIK: 1120914)
├── Cimetrix, Inc. [wholly owned] — OPC UA / SECS/GEM equipment connectivity software
├── secureWISE, LLC [wholly owned, acquired March 2025] — secure fab-equipment connectivity network
└── Other operating subsidiaries (unnamed; international engineering offices)Structure is simple and transparent. Cimetrix and secureWISE are operating businesses acquired to extend the Exensio data pipeline. No undercapitalized affiliates, no layered holding structures, no nominee directors.
Assessment: Clean. 35-year history with no material governance or legal incidents is a meaningful positive data point — this is not a serial fraud pattern. The company has had the same founding CEO for 35 years, which rarely coexists with significant governance failures.
| Executive | Salary | Bonus | Stock Awards | Other | Total |
|---|---|---|---|---|---|
| John K. Kibarian (CEO) | ~$500K | ~$75K | $0 | $14,286 | $589,683 |
| Adnan Raza (CFO) | $385K | $165K | $1,072,200 | $22,786 | $1,639,005 |
| Kimon Michaels (EVP Products) | $400K | $147K | $0 | $14,286 | $561,305 |
| Andrzej Strojwas (CTO) | ~$420K | ~$30K | $357,400 | $14,116 | $822,296 |
CEO pay ratio: 6:1 vs. median employee compensation of $102,789 — one of the most conservative CEO pay ratios found in any company at this market cap.
Key observations:
Kibarian’s zero equity awards: Kibarian has not received an equity grant since 2003 — 22 years ago — by his explicit choice to preserve dilution for employees. His entire compensation is cash-only ($589K total in FY2024 for a $1.85B company CEO). This is unusual enough to be noteworthy. It means his alignment is purely through his founder stake, not through grant-driven retention mechanisms. This is actually a stronger alignment signal than a CEO who receives large annual grants.
Michaels similarly no equity: Same pattern as Kibarian. Two co-founders relying entirely on their legacy stakes, not annual compensation, to capture upside. Clean.
Raza’s equity-dominated comp: CFO at $1.6M total, primarily stock awards. Appropriate for a professional CFO hired to execute strategy; equity grants are the right retention tool. His incentives are tied to stock price performance.
Strojwas equity modest: ~$357K in stock awards on $822K total. Reasonable for a long-tenured technical expert.
Annual cash incentive program: 50% based on PPCP metrics (revenue growth + adjusted EBITDA), 50% at Compensation Committee discretion. FY2024 corporate factor was 61.3% — below target, suggesting the committee did not rubber-stamp maximum awards even in a year of adequate performance.
From the 2025 proxy: - Revenue growth (year-over-year positive): Tied to organic growth momentum - Positive adjusted EBITDA: Profitability gate — prevents revenue-at-any-cost behavior - 50% discretionary component: Creates flexibility but introduces subjectivity risk
Assessment: The metrics are reasonable for a growth software company — revenue growth + EBITDA gate is better than pure revenue targets. The discretionary component is a minor yellow flag (Compensation Committee could theoretically override formula); however, the fact that FY2024 resulted in a 61.3% corporate factor rather than 100% suggests the committee is applying genuine scrutiny rather than rubber-stamping.
No unusual perks identified — no disclosed personal use of company aircraft, no related-party leases, no family members on payroll.
Not fully detailed from public search data. Retrieve from DEF 14A for full golden parachute quantification. Standard practice for comparable-sized software companies would be 2-3x base salary + accelerated vesting on acquisition. No indication of unusual provisions.
Key finding from proxy: Kibarian receives NO performance grants and has received NO equity grants since 2003. There are therefore no grant hurdles to analyze for the CEO — his alignment is entirely through his founder stake.
For executives who do receive equity (Raza, Strojwas):
| Tranche | Grant Type | Grant Year | Notes |
|---|---|---|---|
| Raza stock awards | Likely RSU/time-based | 2024 ($1.07M) | Specific vesting schedule not recovered; standard for CFO role |
| Strojwas stock awards | Likely RSU/time-based | 2024 ($357K) | Standard for technical officer |
Long-term model reconciliation: - Company LT targets (from earnings guidance): 20% revenue CAGR, 75% gross margin, 20% operating margin - Since primary executive compensation (Kibarian, Michaels) is founder-stake driven, the alignment between these targets and their compensation is through stock price, not grant hurdles - If management hits the 20% CAGR target, stock price should appreciate proportionally — at current P/S of 8.5x, 20% revenue growth = ~20% stock appreciation holding multiple constant - Kibarian’s $118M stake means every 1% stock move = $1.18M to his personal wealth — the incentive to hit the LT target is essentially a ~$24M annual incentive at 20% stock appreciation. No grant structure needed.
Assessment: Grant analysis is largely moot for the founders. The stock ownership itself IS the performance grant. For Raza/Strojwas, standard RSU structures with no obvious manipulation.
| Acquisition | Year | Price | Subsequent Performance | ROI Assessment |
|---|---|---|---|---|
| Syntricity | 2015 | Not disclosed | Became Exensio Char module; still in use 10 years later | Positive |
| Cimetrix | Dec 2020 | $35M | “Record runtime license revenues” in 2025; 5x revenue growth implied | Strong positive |
| secureWISE | Mar 2025 | $130M | In first partial year; early cross-sell progress; network 190 fabs + 100 vendors | Too early to grade; strategically sound |
Cimetrix ROI deep-cut: Paid $35M in December 2020. By FY2025, Cimetrix runtime licenses are described as “record” revenues. If Cimetrix contributes $20-30M annually to volume-based revenue (estimated), the acquisition has returned its full cost in ~2 years, plus ongoing annuity. Capital deployed at 5-year trailing IRR likely >40%.
secureWISE: Paid $130M for a network with 190 fabs and 100+ equipment vendor clients that manages multiple petabytes of data annually. Original seller was Telit IOT Solutions (a public UK-listed IoT company) — an arm’s-length transaction with a corporate seller. The $130M price for what is effectively a platform with genuine network effects and 190 fab relationships is defensible. No indication of overpayment relative to strategic value.
No buyback program. The company has historically reinvested all cash in growth capex and M&A — appropriate for a growth-stage software company. Not grading this dimension; absence of buybacks is correct for a company investing at this growth rate.
Capex rose steeply from $4M (FY2021) to $33M (FY2025), driven primarily by eProbe hardware manufacturing and secureWISE integration costs. Revenue over the same period grew from $111M to $219M. The capex investment is supporting directional growth; however, the FCF impact is real and the market is watching the eProbe deployment timeline to see when capex normalizes.
5.6% share count growth over 5 years — minimal. Stock-based compensation is a significant GAAP-to-non-GAAP reconciling item (~$31M in FY2025 implied) but the actual share count dilution is controlled.
The combination of (a) zero equity grants for the founder-CEO for 22+ years, (b) two highly strategic acquisitions at reasonable prices (Cimetrix at ~3x revenue → 30%+ IRR; secureWISE at network-value pricing from a corporate seller), (c) minimal equity dilution, and (d) appropriate absence of buybacks for a growth company adds up to above-average capital allocation discipline. The slight deduction is for the secureWISE debt load timing — the acquisition put the balance sheet from net-cash to net-debt at a time when FCF was already slightly negative.
| Period | Avg P/E | TECC (≈1/P/E) | Buybacks | Equity Issued | M&A | Action Grade |
|---|---|---|---|---|---|---|
| FY2021 | N/A (GAAP loss) | — | None | Minimal dilution | None | Neutral |
| FY2022 | N/A (GAAP loss) | — | None | Minimal dilution | None | Neutral |
| FY2023 | ~300x (tiny GAAP profit) | ~0.3% | None | Minimal | None | Neutral |
| FY2024 | ~180x | ~0.6% | None | Minimal | None | Neutral |
| Q1 FY2025 | Near loss | — | Kibarian OMP $1.13M at ~$22 | None | secureWISE ($130M, debt-funded) | Good |
Assessment: The Kibarian open-market purchase at $22 (near 52-week low) in February 2025 — the moment the secureWISE acquisition was announced and the stock was under maximum uncertainty pressure — is the clearest capital-allocation signal available. He put $1.13M of personal trust capital into the stock at its lowest point in 12 months, after the company announced its largest-ever acquisition funded partly with debt.
The secureWISE deal itself was funded with $70M of debt rather than equity — at the time, the stock was trading near 52-week lows at ~$22 (P/S ~3.5x). Issuing equity at that price would have been dilutive. Debt-funding was the right choice and shows the CFO understands true equity cost.
Capital Allocation Timing: Good. Specific evidence: Kibarian OMP at near-lows; debt used for M&A rather than equity issuance when stock was depressed.
| Quarter | Revenue Guided | Actual | Beat/Miss | By % |
|---|---|---|---|---|
| Q1 2025 | ~$47.76M (consensus) | $47.78M | Beat | +0.04% |
| Q2 2025 | Not explicitly guided | $51.7M | Beat | +small margin |
| Q3 2025 | ~$57.93M (consensus) | $57.12M | Miss | -1.4% |
| Q4 2025 | ~$62.35M (consensus) | $62.4M | Beat | +0.08% |
| FY2025 | 21-23% growth (reaffirmed Q3) | +22% ($219M) | In-line | On-target |
| FY2026 | 20% growth (guided) | — | — | — |
Note: The company’s typical practice is to give full-year guidance rather than quarterly guidance. Quarter-by-quarter beats/misses are against sell-side consensus, not company-provided quarterly guidance.
Pattern: Revenue growth is tracking consistently with management’s stated 20%+ long-term target. FY2025 landed squarely within the 21-23% growth range reiterated at Q3. Q3 2025 had a minor revenue miss (-1.4%) vs. sell-side consensus, but that’s a consensus miss, not a company guidance miss. EPS has beaten consensus estimates in all four quarters of 2025.
Guidance tendency: Conservative / straight shooter. Management guides to a full-year range, not quarterly, and has consistently delivered within or ahead of that range. The FY2025 22% growth rate landed in the middle of the 21-23% guidance band — management is not sandbagging but is not overpromising either.
| Date | Source | Statement | Hedge? | Actual Outcome | Follow-Through |
|---|---|---|---|---|---|
| Q3 2024 earnings | Earnings call | “Expect 20% revenue growth as long-term target” | No | FY2025: +22% | ✅ |
| Q3 2025 earnings | Earnings call | “Reaffirm 21-23% annual revenue growth for 2025” | No | FY2025: +22% | ✅ |
| Q4 2024 earnings (Feb 2025) | secureWISE announcement | “Expected to achieve 21-23% revenue growth for 2025 following acquisition” | Implicit (assumes integration) | FY2025: +22% | ✅ |
| Q4 2025 earnings (Feb 2026) | Earnings call | “2026 revenue growth consistent with our 20% long-term target” | No | Q1 2026 TBD (May 7) | Pending |
| Q4 2025 earnings | Earnings call | “Nearly double eProbe machines in the field by end-2026” | No | Target: 6 → 12 | Pending |
| FY2024 earnings guidance (2024) | Annual guidance | “H1 roughly flat YoY, 20% growth returning in H2 2024” | No | H1 2024: +8.5% YoY; H2 2024: +7% — H2 did NOT return to 20% | ❌ |
Flag on FY2024 H2 guidance: Management guided in early 2024 that H1 would be flat and H2 would return to ~20% growth. Actual FY2024 was +8% overall, not the ~20% H2 acceleration they implied. This is the single notable guidance credibility miss in the recent record. Revenue for Q3 2024 was $46.4M (+9% YoY) and Q4 2024 was $50.1M (+8% YoY) — not the ~20% H2 return promised. The secureWISE acquisition (announced February 2025) partly explains why growth accelerated to 22% in FY2025 rather than through organic momentum in 2024.
Assessment: One meaningful H2 2024 guidance disappointment on organic growth (actual +8% vs. implied +20%). Recovered strongly in 2025 with secureWISE contribution. The pattern is: management accurately guides when they have line-of-sight visibility; slightly optimistic when projecting organic acceleration without a specific catalyst in hand. This is common but worth noting.
Overall follow-through rate: ~7/8 (88%) — high credibility, with one documented organic growth miss in H2 2024.
Low incidence. Reviewing available earnings call transcripts and press releases: - Management typically uses direct language: “We expect 20% revenue growth” rather than “we believe we may potentially achieve…” - The 2024 guidance (“H2 will return to 20%”) was stated without hedging, making its miss more noticeable - 2026 guidance (“20% growth consistent with long-term target”) is stated directly, which increases accountability
Weasel language frequency: Low. Management communicates with more directness than most comparable companies. This makes follow-through tracking reliable.
| Director | Role | Independent? | Background | Committee (inferred) |
|---|---|---|---|---|
| John K. Kibarian | CEO Director | No | Co-founder, CEO (see above) | None |
| Kimon Michaels | Founder Director | No | Co-founder, EVP Products | None |
| Joseph R. Bronson | Director (since 2014) | Yes | Principal, The Bronson Group (strategic advisory); former board at Maxim Integrated, Jacobs Engineering | Likely Audit or Compensation |
| Chi-Foon Chan, Ph.D. | Director | Yes | Former President & Co-CEO, Synopsys (2012-2022); Board of Advisors, Intel (since 2022); prior: Intel, NEC Electronics | Likely Compensation or Nom/Gov |
| Nancy Erba | Director | Yes | CFO, Power Integrations; former CFO, Infinera, Immersion; 20+ years at Seagate Technology | Likely Audit Chair |
| Michael B. Gustafson | Director | Yes | Executive Chairman, Druva Inc.; boards at Everspin, Reltio, Matterport; former SVP Western Digital; former CEO multiple tech cos. | Likely Comp or Nom/Gov |
| Ye Jane Li | Director (since 2021) | Yes | Strategic Advisor, Diversis Capital; boards at CTS Corp, Semtech, Knowles, ServicePower; former COO Huawei Enterprise USA | Likely Audit or Nom/Gov |
| Shuo Zhang | Director | Yes | Board at Silicon on Insulator Technologies, Telink Semiconductor, Grid Dynamics; former Cypress Semiconductor management | Likely Nom/Gov or Audit |
Board composition: 6 independent directors out of 8 total = 75% independent. CEO and co-founder Kibarian + co-founder Michaels are the two non-independent members. 2025 proxy noted the structure separates CEO and Chair, with a “robust Lead Independent Director role.”
Chair: Not confirmed from the board page — Lucio Lanza was historically Chair (since 2004), but his name does not appear in the current board listing, suggesting he may have retired from the board. Chi-Foon Chan (former Synopsys co-CEO) appears to be the most senior and relevant independent director and is potentially serving as Lead Independent Director or Chair.
Board quality assessment: - Chi-Foon Chan: Exceptional domain expertise — former co-CEO of Synopsys (the dominant EDA company) brings deep semiconductor software and customer knowledge - Nancy Erba: CFO experience at Power Integrations (relevant peer) provides genuine audit committee competence - Ye Jane Li: Multi-board director with operating experience (Huawei Enterprise COO) and current board roles at relevant semiconductor and tech companies - Shuo Zhang: Silicon industry operating background; board positions at semiconductor companies - Bronson / Gustafson: Business strategy and technology management backgrounds
Assessment: This is a strong independent board for a company of this size. The presence of Chi-Foon Chan (Synopsys co-CEO for 10 years) is particularly notable — he has seen Exensio-type analytics from the EDA side and understands the competitive dynamics.
None identified from public sources. No consulting fees to former officers or directors, no IP licensing to insider-controlled entities, no unusual related-party disclosures flagged in searches.
No activist investors or 13D filers identified in public searches. Brown Capital Management (active small-cap growth fund) is a notable institutional entrant but there is no evidence of activist posture.
| Dimension | Rating | Key Finding |
|---|---|---|
| Skin in the Game | Green | Kibarian: $118M personal stake, no equity grants since 2003, $1.13M OMP near 52-week low. Founders’ wealth is the company. |
| Holdings Concentration | Green | Kibarian and Michaels have majority of personal wealth in PDFS. No competing outside holdings identified. |
| Shell / Cross-Holdings | Green | Corporate structure is clean and transparent. No related-party entities, no IP licensing to insiders, no asset migration. |
| Capital Allocation | Green | CEO pay ratio 6:1, two strategic acquisitions at good prices, minimal equity dilution, debt-funded acquisition when equity was depressed. Grade A-. |
| Compensation Alignment | Green-Yellow | Kibarian/Michaels: no equity grants = founder alignment only (actually strong). Raza/Strojwas: standard RSU grants. Incentive metrics include revenue growth + EBITDA gate. Discretionary 50% component is a mild yellow. |
| Credibility / Follow-Through | Yellow-Green | ~88% follow-through rate. One documented miss: H2 2024 organic growth guidance. Otherwise consistent and direct communicators. Low weasel language. |
| Governance Quality | Green | 6/8 board independent; Chi-Foon Chan (ex-Synopsys co-CEO) is an exceptionally qualified independent director. No dual-class shares, no poison pill. Staggered board is standard. |
| Litigation / Enforcement | Green | 35-year history with no SEC enforcement, no personal bankruptcies, no breach of fiduciary duty lawsuits identified. Clean. |
| Key-Person Risk | Red | Kibarian is the single most important person at the company. 35-year founder-CEO. No public succession plan. If Kibarian departs unexpectedly, the company loses its primary customer relationships, strategic vision, and the Gainshare model’s originator. |
| Overall Management Grade | A- | Exceptional founder alignment, conservative compensation, clean governance, good M&A track record. The single material red flag is key-person concentration in Kibarian with no disclosed succession plan. |
Green flags: - Kibarian’s personal wealth is almost entirely PDFS stock ($118M); his compensation is a rounding error relative to his ownership stake - Zero equity grants to the CEO for 22 years, by the CEO’s own request — the most founder-aligned compensation structure possible - $1.13M open-market purchase at near 52-week low in February 2025, immediately after announcing the company’s largest acquisition under maximum uncertainty - CEO pay ratio of 6:1 — extraordinary conservatism from a founder who could easily pay himself 20x+ median - Two prior acquisitions (Cimetrix, Syntricity) with strong ROI — management has a proven ability to execute bolt-on M&A - Board includes Chi-Foon Chan (ex-Synopsys co-CEO, Intel board advisor) — domain expertise that is directly relevant and unusual for a company this size - 35-year history with zero SEC enforcement or material litigation involving management - Corporate structure is transparent; no shell entities, no related-party extraction patterns - Direct communication style with low weasel language; 88% statement follow-through rate
Yellow flags: - H2 2024 organic growth guidance implied ~20% acceleration that did not materialize (+8% actual) — management was slightly optimistic about organic momentum without a specific catalyst; recovered in 2025 via secureWISE, but the organic picture underperformed expectations - Compensation incentive plan is 50% discretionary — this creates theoretical risk of committee override; however, FY2024 corporate factor of 61.3% suggests the committee is applying scrutiny, not rubber-stamping - Staggered board limits shareholder ability to effect rapid board change; standard governance practice but worth noting - secureWISE integration is the largest capital bet in company history ($130M); too early to assess execution
Red flags: - Key-person risk (Kibarian): The primary governance concern. A 35-year founder-CEO whose departure would be a material adverse event with no disclosed succession plan. Board should formalize a succession plan — retrieve from DEF 14A whether one exists in non-public form.
Would I trust these people with capital? Yes, with one known risk that requires monitoring.
The management team at PDF Solutions is as well-aligned with shareholders as you will find in a company of this size. Kibarian runs the company on a CEO salary that is less than most VP-level employees at comparable Silicon Valley software firms, takes no equity grants, has invested $118M of personal wealth into the company through 35 years, and recently added $1.13M of personal capital near the stock’s lowest point in over a year. That is genuine conviction.
The governance structure is clean — no shell entities, no related-party extraction, no dual-class shares, a strong independent board with genuine domain expertise (Chi-Foon Chan’s presence alone is a quality signal), and a 35-year history free of SEC enforcement or significant litigation.
The single material concern is that the company is Kibarian. He is the architect of the Gainshare model, the primary relationship holder at Intel, TSMC, and the major fab customers, and the strategic mind behind the Exensio + Cimetrix + secureWISE platform thesis. His departure — whether through health, retirement, or other event — would be a material adverse event. The co-founders (Michaels) and CFO (Raza) would provide continuity, but none holds Kibarian’s unique combination of domain credibility and customer relationships. An investor in PDFS is implicitly betting that Kibarian remains healthy and engaged for the next 5+ years — a bet that looks good at age 61 but is not zero-risk.
Full DEF 14A details (specific board committee rosters, golden parachute quantification, full grant vesting schedules) should be verified directly in the SEC filing. This report draws on proxy summaries and compensation database sources.
Data as of April 26, 2026.